Despite pharmacovigilance legislation being in place for nearly a decade, many companies are still struggling to fulfill obligations. Arriello's Vanessa Fachada Oliveira writes for Pharmaceutical Technology
Streamlining Pharmacovigilance: Why the Inertia? via Pharmaceutical Executive and Arriello's Director of Drug Safety Peter Kohut analyse the findings of a survey on how life sciences companies are capitalizing on opportunities to transform workload and data quality management using the latest smart technology.
Why aren’t more companies automating PV data capture?
Why are Safety & Pharmacovigilance departments lagging in their application of smart technology, when the pressures on pharmaceutical organisations to capture, sift and process real-world adverse event data are vast, asks John Price, a life sciences regulatory and safety consultant and advisor to Arriello.
Raising the bar in pharmacovigilance and regulatory outsourcing.
It’s all too easy to underestimate the importance of tight project management when the work being outsourced is something other than clinical trials. Yet, whether the processes involved concern international pharmacovigilance or regulatory information filing, Anna Lukyanova, COO of Arriello, warns life sciences firms not to leave outcomes to chance.
We use cookies to improve our website by collecting visit information without directly identifying its users or collecting sensitive information. Click Accept to consent to this collection or Reject to decline it.
Arriello 
